CEFTOBIPROLE MEDOCARIL SODIUM - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for ceftobiprole medocaril sodium and what is the scope of patent protection?

Ceftobiprole medocaril sodium is the generic ingredient in one branded drug marketed by Basilea Pharm Allsch and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for CEFTOBIPROLE MEDOCARIL SODIUM

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Applications:	8
DailyMed Link:	CEFTOBIPROLE MEDOCARIL SODIUM at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for CEFTOBIPROLE MEDOCARIL SODIUM

Generic Entry Date for CEFTOBIPROLE MEDOCARIL SODIUM^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: GENERATING ANTIBIOTIC INCENTIVES NOW Dosage: POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for CEFTOBIPROLE MEDOCARIL SODIUM

J01DI	Other cephalosporins and penems
J01D	OTHER BETA-LACTAM ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for CEFTOBIPROLE MEDOCARIL SODIUM

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Basilea Pharm Allsch	ZEVTERA	ceftobiprole medocaril sodium	POWDER;INTRAVENOUS	218275-001	Apr 3, 2024		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Basilea Pharm Allsch	ZEVTERA	ceftobiprole medocaril sodium	POWDER;INTRAVENOUS	218275-001	Apr 3, 2024		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Summary for CEFTOBIPROLE MEDOCARIL SODIUM

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for CEFTOBIPROLE MEDOCARIL SODIUM

Anatomical Therapeutic Chemical (ATC) Classes for CEFTOBIPROLE MEDOCARIL SODIUM

Make Better Decisions: Try a trial or see plans & pricing

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for CEFTOBIPROLE MEDOCARIL SODIUM